雍禾医疗:连年亏损销售费用畸高,多子公司成被执行人、大量子公司注销

九号观察
Jun 30, 2025

来源 | 九号观察作者 | 跳跳作为“植发第一股”的雍禾医疗,自2021年登陆港交所以来,万万没想到出道即巅峰,上市不久后股价就一路下行,至今市值还不足8亿元,业绩也在上市后第二年就变脸,2022年至今连年亏损,至于营收,上市当年达到高峰后就再也没起来过。业绩连续亏损的背后,是雍禾医疗销售费用的长期畸高,销售费用占营收的比重常年超过50%,而研发费用则长期徘徊在一两千万。而今年以来雍禾医疗旗下有...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10